ARCELLX INC's ticker is and the CUSIP is 03940C100. A total of 127 filers reported holding ARCELLX INC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $162,800,189 | +9.8% | 4,537,352 | -3.3% | 0.01% | +16.7% |
| Q2 2023 | $148,329,357 | -10.3% | 4,690,998 | -12.6% | 0.01% | +50.0% |
| Q1 2023 | $165,332,004 | +312.5% | 5,366,180 | +314.8% | 0.01% | +100.0% |
| Q4 2022 | $40,075,728 | +170.7% | 1,293,600 | +64.0% | 0.00% | +100.0% |
| Q3 2022 | $14,803,000 | +31.3% | 788,668 | +26.4% | 0.00% | +100.0% |
| Q2 2022 | $11,277,000 | – | 623,718 | +4797730.8% | 0.00% | – |
| Q1 2022 | $0 | – | 13 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | 5,500,007 | $170,390,217 | 62.20% |
| PATHWAY CAPITAL MANAGEMENT, LP | 189,120 | $5,858,938 | 10.46% |
| NEA Management Company, LLC | 4,745,262 | $147,008,217 | 8.26% |
| Samsara BioCapital, LLC | 957,451 | $29,661,832 | 6.38% |
| Soleus Capital Management, L.P. | 1,102,447 | $34,153,808 | 4.90% |
| Cormorant Asset Management, LP | 2,075,000 | $64,284 | 4.30% |
| Paradigm Biocapital Advisors LP | 882,101 | $27,327,489 | 3.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,350,333 | $72,813,316 | 3.06% |
| Affinity Asset Advisors, LLC | 240,143 | $7,439,630 | 2.92% |
| CAXTON CORP | 36,302 | $1,124,640 | 2.87% |